Latest Commercial Agreements News

Cyclone Metals has secured a pivotal development agreement with Vale, unlocking up to USD 138 million in funding for the Iron Bear iron ore project in Canada and setting a clear path to production.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Bass Oil Limited is set to deepen its exploration of the Triassic gas play in the northern Cooper Basin following a successful flow test at the Kiwi gas field, signaling significant potential for future discoveries and development.

Lindian Resources has awarded a $1.3 million contract to Mota-Engil for the construction of a critical access road at its Kangankunde Rare Earths Project in Malawi, marking a key milestone in project development and local infrastructure enhancement.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

NH3 Clean Energy has successfully completed the Pre-FEED engineering phase for its WAH2 clean ammonia project, unlocking new opportunities for emissions and cost optimization while preparing for strategic partnerships.

Yojee's December quarter report reveals solid transaction growth, successful Global Air deployment in Singapore, and promising progress on its MOSAIC platform, supported by a strong cash position and no debt.

Bass Oil Limited reported a 27% drop in quarterly revenue amid natural production declines but highlighted promising developments in its Kiwi gas field project in the Cooper Basin.

IODM Limited reported a robust 49.4% increase in Q2 FY25 cash receipts, driven by explosive growth in its UK Education segment and strategic onboarding of prestigious universities.

Stonehorse Energy Limited outperformed production forecasts in Q4 2024 despite a revenue dip caused by weak natural gas prices, while advancing new project negotiations in Canada and the US.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.